INSERM U1030, Molecular Radiation Therapy and Therapeutic Innovation, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France; Labex LERMIT, DHU TORINO, SIRIC SOCRATE, Villejuif, France.
INSERM U1030, Molecular Radiation Therapy and Therapeutic Innovation, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France; Labex LERMIT, DHU TORINO, SIRIC SOCRATE, Villejuif, France; Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1283-1294. doi: 10.1016/j.ijrobp.2021.03.022. Epub 2021 Mar 13.
Severe pneumonia and acute respiratory distress syndrome (ARDS) have been described in patients with severe coronavirus disease 2019 (COVID-19). Recently, early clinical data reported the feasibility of low doses of radiation therapy (RT) in the treatment of ARDS in patients with severe COVID-19. However, the involved mechanisms remained unknown.
Here, we used airways-instilled lipopolysaccharide (LPS) and influenza virus (H1N1) as murine models of pneumonia, and toll-like receptor (TLR)-3 stimulation in human lung macrophages.
Low doses of RT (0.5-1 Gray) decreased LPS-induced pneumonia, and increased the percentage of nerve- and airway-associated macrophages producing interleukin (IL) 10. During H1N1 viral infection, we observed decreased lung tissue damage and immune cell infiltration in irradiated animals. Low doses of RT increased IL-10 production by infiltrating immune cells into the lung. Irradiation of TLR-3 ligand-stimulated human lung macrophages ex vivo increased IL-10 secretion and decreased interferon γ production in the culture supernatant. The percentage of human lung macrophages producing IL-6 was also decreased.
Our data highlight a mechanism by which low doses of RT regulate lung inflammation and skew lung macrophages toward an anti-inflammatory profile. These data provide a preclinical mechanistic support to clinical trials evaluating low doses of RT, such as COVID-19-induced ARDS.
严重肺炎和急性呼吸窘迫综合征(ARDS)已在严重 2019 冠状病毒病(COVID-19)患者中描述。最近,早期临床数据报告了低剂量放射治疗(RT)在治疗严重 COVID-19 患者 ARDS 中的可行性。然而,涉及的机制仍不清楚。
在这里,我们使用气道内注入脂多糖(LPS)和流感病毒(H1N1)作为肺炎的小鼠模型,以及人肺巨噬细胞中 Toll 样受体(TLR)-3 刺激。
低剂量 RT(0.5-1 Gray)可降低 LPS 诱导的肺炎,并增加产生白细胞介素(IL)10 的神经和气道相关巨噬细胞的百分比。在 H1N1 病毒感染期间,我们观察到照射动物的肺组织损伤和免疫细胞浸润减少。低剂量 RT 增加了浸润到肺部的免疫细胞产生 IL-10。体外照射 TLR-3 配体刺激的人肺巨噬细胞可增加培养上清液中 IL-10 的分泌并减少干扰素γ的产生。产生 IL-6 的人肺巨噬细胞的百分比也降低。
我们的数据强调了低剂量 RT 调节肺部炎症并使肺部巨噬细胞向抗炎表型倾斜的机制。这些数据为评估 COVID-19 诱导的 ARDS 等低剂量 RT 的临床试验提供了临床前机制支持。